AIM: To explore cancer cell-specific phage fusion pVIII coat protein, identified using phage display, for targeted delivery of drug-loaded liposomes to MCF-7 breast cancer cells. MATERIAL & METHODS: An 8-mer landscape library f8/8 and a biopanning protocol against MCF-7 cells were used to select a landscape phage protein bearing MCF-7-specific peptide. Size and morphology of doxorubicin-loaded liposomes modified with the tumor-specific phage fusion coat protein (phage-Doxil) were determined by dynamic light scattering and freeze-fraction electron microscopy. Topology of the phage protein in liposomes was examined by western blot. Association of phage-Doxil with MCF-7 cells was evaluated by fluorescence microscopy and fluorescence spectrometry. Selective targeting to MCF-7 was shown by FACS using a coculture model with target and nontarget cells. Phage-Doxil-induced tumor cell killing and apoptosis were confirmed by CellTiter-Blue Assay and caspase-3/CPP32 fluorometric assay. RESULTS: A chimeric phage fusion coat protein specific towards MCF-7 cells, identified from a phage landscape library, was directly incorporated into the liposomal bilayer of doxorubicin-loaded PEGylated liposomes (Doxil) without additional conjugation with lipophilic moieties. Western blotting confirmed the presence of both targeting peptide and pVIII coat protein in the phage-Doxil, which maintained the liposomal morphology and retained a substantial part of the incorporated drug after phage protein incorporation. The binding activity of the phage fusion pVIII coat protein was retained after incorporation into liposomes, and phage-Doxil strongly and specifically targeted MCF-7 cells, demonstrating significantly increased cytotoxicity towards target cells in vitro. CONCLUSION: We present a novel and straightforward method for making tumor-targeted nanomedicines by anchoring specific phage proteins (substitute antibodies) on their surface.
AIM: To explore cancer cell-specific phage fusion pVIII coat protein, identified using phage display, for targeted delivery of drug-loaded liposomes to MCF-7 breast cancer cells. MATERIAL & METHODS: An 8-mer landscape library f8/8 and a biopanning protocol against MCF-7 cells were used to select a landscape phage protein bearing MCF-7-specific peptide. Size and morphology of doxorubicin-loaded liposomes modified with the tumor-specific phage fusion coat protein (phage-Doxil) were determined by dynamic light scattering and freeze-fraction electron microscopy. Topology of the phage protein in liposomes was examined by western blot. Association of phage-Doxil with MCF-7 cells was evaluated by fluorescence microscopy and fluorescence spectrometry. Selective targeting to MCF-7 was shown by FACS using a coculture model with target and nontarget cells. Phage-Doxil-induced tumor cell killing and apoptosis were confirmed by CellTiter-Blue Assay and caspase-3/CPP32 fluorometric assay. RESULTS: A chimeric phage fusion coat protein specific towards MCF-7 cells, identified from a phage landscape library, was directly incorporated into the liposomal bilayer of doxorubicin-loaded PEGylated liposomes (Doxil) without additional conjugation with lipophilic moieties. Western blotting confirmed the presence of both targeting peptide and pVIII coat protein in the phage-Doxil, which maintained the liposomal morphology and retained a substantial part of the incorporated drug after phage protein incorporation. The binding activity of the phage fusion pVIII coat protein was retained after incorporation into liposomes, and phage-Doxil strongly and specifically targeted MCF-7 cells, demonstrating significantly increased cytotoxicity towards target cells in vitro. CONCLUSION: We present a novel and straightforward method for making tumor-targeted nanomedicines by anchoring specific phage proteins (substitute antibodies) on their surface.
Authors: Peter Hölig; Miriam Bach; Tina Völkel; Thomas Nahde; Sven Hoffmann; Rolf Müller; Roland E Kontermann Journal: Protein Eng Des Sel Date: 2004-07-02 Impact factor: 1.650
Authors: Frank Alexis; June-Wha Rhee; Jerome P Richie; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad Journal: Urol Oncol Date: 2008 Jan-Feb Impact factor: 3.498
Authors: Tao Wang; Nikita Kulkarni; Gerard G M D'Souza; Valery A Petrenko; Vladimir P Torchilin Journal: Mol Pharm Date: 2011-07-29 Impact factor: 4.939
Authors: Tao Wang; Radhika Narayanaswamy; Huilan Ren; James W Gillespie; Valery A Petrenko; Vladimir P Torchilin Journal: J Drug Target Date: 2017-12-01 Impact factor: 5.121
Authors: Tao Wang; Shenghong Yang; Leslie A Mei; Chirag K Parmar; James W Gillespie; Kulkarni P Praveen; Valery A Petrenko; Vladimir P Torchilin Journal: Mol Cancer Ther Date: 2014-09-19 Impact factor: 6.261
Authors: Victor Y Lee; Karen Havenstrite; Melia Tjio; Melanie McNeil; Helen M Blau; Robert D Miller; Joseph Sly Journal: Adv Mater Date: 2011-09-08 Impact factor: 30.849
Authors: Aristarchos Papagiannaros; Valeria Righi; George G Day; Laurence G Rahme; Philip K Liu; Alan J Fischman; Ronald G Tompkins; A Aria Tzika Journal: Adv J Mol Imaging Date: 2012-10
Authors: Deepa Bedi; James W Gillespie; Vasily A Petrenko; Andreas Ebner; Michael Leitner; Peter Hinterdorfer; Valery A Petrenko Journal: Mol Pharm Date: 2013-01-08 Impact factor: 4.939